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ABSTRACT 
 
Parkinson's disease is characterized by dopaminergic-cell loss in the substantia nigra in the basal ganglia. Natural 
dietary antioxidants may exert protection against age-related deficits in cognitive and motor function.  Present work 
conducted to evaluate the effects of some natural products in animal model of Parkinsonism which induced   by 
rotenone injection (1.5 mg/kg s.c). Rats divided into 6 groups: - 1stcontrol: rats injected with rotenone 6 doses every 
other day for 11days, 2nd normal: rats injected i.p. with 1% cremophor, , injected s.c.  DMSO.  3rd, 4th, 5th, 6th: rats 
given deprenyl (10 mg/kg, s.c), naringenin (50 mg/kg, p.o), harmine (5 mg/kg, i.p) & adenosine (500 mg/kg, i.p) 6 
doses every other day for 11 days, 1 hour before rotenone injection. 24th after the last doses of all treatments, 
behavioural tests, rotarod and activity cage performed .At the end of the experiment, rats decapitated and brain 
removed for determination of brain neurotransmitters content as dopamine and its metabolite [dopamine (DA), 3,4 
dihydroxyphenylacetic acid (DOPAC) and  homovanilic acid (HVA)] and oxidative stress biomarkers as glutathione, 
malondialdehyde, nitric oxide (NOx) content . Results revealed that deprenyl and naringenin improved rats' 
locomotor activity, while, harmine and adenosine decreased the locomotor activity. Deprenyl, harmine, naringenin 
improved rats balancing time. Deprenyl and naringenin increased the dopamine content. Deprenyl, naringenin, harmine 
and adenosine treatment resulted in increased glutathione with decrease of malondialdehyde brain content. These 
findings suggested that all three tested agents improved the oxidative status induced by rotenone, however, 
naringenin and harmine counteracted the decrease in dopamine content.  
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INTRODUCTION 
 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder with a prevalence of 0.5-1% in 
individuals of 65 -96 years and 1-3% among individuals of 80 years [55 ]. It is clinically characterized by four 
cardinal features: Resting tremors, postural instability, bradykinesia— these symptoms are attributed primarily but 
not exclusively to the selective loss of dopaminergic neurons in SNc (50-70% of dopaminergic neurons), which 
believed to be the most crucial [ 7, 13 , 56] .Surviving neurons may contain Lewy bodies, intracytoplasmic protein 
aggregates mainly composed of α-synuclein and believed to be a second neuropathological feature of PD [ 64 ,69 ]. 
The hypotheses for sporadic PD include combinations of the aging process, genetic propensity and environmental 
exposures hypothesis which posits that exposure to pesticides appears to correlate strongly with increased incidence 
of Parkinsonism [ 22, 23 , 63 ], for example, The pesticide rotenone, a highly selective complex I inhibitor may 
produce neuropathological features of PD in rats [ 6 ,67 ]. 
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Based on several studies of cellular model analysis and in vitro experiment, it has become obvious that the toxic 
effect of rotenone is multifactorial; the insecticide might express its toxicity via the inhibition of complex I or the 
enhancement of activated microglia or the increased production of ROS or the increased oxidative damage of 
proteins, lipids and DNA [74 ].Hence Rotenone is used in the current work as the induction model of PD. Rotenone 
is a commonly used organic pesticide extracted from Leguminosae plant and has a variety of known biological 
effects [ 54 , 65] . 
 
Neuroprotection can be considered a form of therapy to slow the rate of progression of a neurodegenerative disease. 
Concepts of potential neuroprotective approaches for PD have developed over the last decade and focused on agents 
that reduce oxidative stress, combat excitotoxicity, enhance mitochondrial function, counteract inflammation and 
inhibit apoptosis. Currently available anti-parkinsonian agents exert several undesirable side effects. The 
development of safe and effective agents of natural origin may provide a better way to improve the patient's 
condition and lessen side effects.   
 
 Treatment with the plant extracts rich in polymethoxylated flavones, procyanidins and isoflavones (e.g. tangeretine 
peel and red clover) significantly attenuated the 6-OHDA-induced dopaminergic loss in rats [12].There is evidence 
that some phenolics can cross BBB. Several animal studies claiming that monophenols (hesperitin and naringenin) 
can enter BBB [84]. However, polyphenols found in fruits such as blueberries are not only powerful antioxidants but 
can exert many other biological effects that may account for some of the neuroprotective actions. Altering stress 
signaling and neuronal communication, suggests that the dietary antioxidants may exert protection against pre-age 
related deficits in cognitive and motor function [35 , 46]  
 
Naringenin (4-oxo, 5,7-trihydroxy flavonone) is a plant bioflavonoid that belong to the class of flavonoids found in 
grapefruit [ 17 ]. Studies by Youdim et al. [80 ,81] indicated that naringenin is able to traverse the BBB. Naringenin 
have already been pharmacologically evaluated as a potential antioxidant [61 ],through direct and indirect 
antioxidant activity corresponding to several steps in the cascade of oxidative events as well as neurodegenerative 
processes like Alzheimer’s, dementia and Parkinson’s diseases [ 33 , 78 ]. 
 
Harmine is one of the β-carbolines which is a class of alkaloids, known as harmala alkaloids, bind with high affinity 
receptors in the brain such as 5-hydroxytryptamine receptor subtypes (5-HT2, 5-HT1A), imidazoline receptors and 
glutamate receptor of the type N-methyl-D-aspartate (NMDA) [14, 25, 47 ]. Therefore, B-Carbolines protect 
neurons against the excitotoxic effects of dopamine and glutamate [45], influence cerebral neurotransmitters [70 ] 
and display a protective effect on oxidative neuronal damage through a scavenging action on reactive oxygen 
species [38, 42 ,58]. 
 
Adenosine is an endogenous purine nucleoside that modulates many physiological processes. Studies suggest that 
some degree of dopaminergic activity is needed to obtain adenosine antagonistic-induced motor activity. Furthermore, 
blockade of dopaminergic neurotransmission counteracts the antagonistic effect induced by adenosine [19 ]. Thus, it 
seems that monotherapy with A2A antagonists may only be useful in the early stages of Parkinson’s disease while 
selective antagonists of the adenosine A2A receptors are widely used in treatment of Parkinson’s disease [21,36 ]  
 
Therefore, it seemed interesting to test the neuroprotective effects of naringenin (50 mg/kg, p.o), harmine (5 
mg/kg,i.p) and adenosine (500 mg/kg, i.p) in rotenone induced PD animal model. The effect of the three drugs was 
compared to that of deprenyl, a standard antiparkinsonian drug with known antioxidant properties. In order to 
achieve the goal of the present study, PD was induced in rats using rotenone (1.5 mg/kg, s.c) dissolved in DMSO 
injected on every other day for eleven days. Behavioral changes which might occur as a result of the induced 
disorder were recorded using the rotarod and the activity cage tests. Furthermore, dopamine content and its metabolites 
in rats' striata were estimated. Brain oxidative stress biomarkers namely, malondialdehyde, reduced glutathione and nitric 
oxide were also assessed. 
 
MATERIALS AND METHODS 
 
Animals: 
Adult male albino Wister rats, weighing 180-200 g, obtained from the animal house of the National Research Center 
(Dokki, Giza, Egypt), were used in the current study. Rats were allowed at least one week of acclimatization before 
using them in the current experiments. All animals housed in plastic cages five per cage and kept in a conditioned 
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atmosphere at 25°C and 60% humidity. The animals were fed standard laboratory pellets (20% proteins, 5% fats and 
1% multivitamins) with tap water ad libitum. Pellets were obtained from the animal house colony of the National 
Research Center (Dokki, Giza, Egypt). Animal procedures were performed in accordance with the Ethics Committee 
of the National Research Centre and Ethics Committee of Faculty of Pharmacy Cairo University. 
 
Drugs and natural products: 
All drugs, unless otherwise specified are purchased from Sigma Chemicals Co.,St. Louis, MO, US. All test agents 
were freshly prepared in 1% camphor in normal saline either for subcutaneous, intraperitoneal or oral administration 
except for rotenone that was dissolved in dimethylsulfoxide (DMSO) for subcutaneous administration. The concentration 
was adjusted so that each 100 gm body weight received 1ml of drug suspension for oral administration and 0.2 ml for 
intraperitoneal and subcutaneous injections. 
 
Experimental Design: 
Behavioural training session: 
Rats were subjected to three days training sessions before injection of the tested drugs using rotarod  in order to 
reach a stable performance on the rod, and on the fourth day rats were placed in the activity cage to habituate them 
to the apparatus and to record their basal activity [75].  
 
Treatment:  
On the fifth day of the training sessions, rats were divided into six groups, 15-20 rats each as following: 1stcontrol 
(rotenone) group: rats were injected s.c.  with rotenone (1.5mg/kg),  6 doses, every other day for eleven days to 
induce experimental PD [72]. 2nd normal group: rats were injected i.p. with 1% cremophor in normal saline, and 
injected s.c. with equivalent volume of DMSO. 3rd, 4th, 5th, 6th groups: rats were given deprenyl 10 mg/kg, s.c  [40 ], 
naringenin 50 mg/kg, p.o [ 84 ], harmine  5 mg/kg, i.p [ 52 ] and adenosine 500 mg/kg, i.p [83] respectively 6 doses 
,every other day for eleven days,1 hour  before rotenone injection. 
 
Behavioral tests:   
Behavioral tests namely rotarod for measurement of motor coordination and activity cage to test locomotor activity 
were performed to surviving rats twenty four hours after the last dose of the treatments. 
 
- Rotarod test: 
All rats used in the present study (except for outliers) were pre-trained on the rotarod apparatus in order to reach a 
stable performance (the average time in seconds spent on the rod). The training consisted of three sessions on three 
consecutive days before the injection of the tested drugs, where each session included three separate testing trials. 
Rats were first habituated to the stationary rod, and then accelerating speed was initiated at 4 rpm and increased 
gradually to reach 40 rpm over 300 seconds. By the last training session all selected rats had reached a stable rotarod 
performance and the average time spent on the rod in the three consecutive trials was used for the baseline 
calculation of rotarod performance [43]. Twenty four hours after the last dose of the tested drugs rats were then 
placed on the testing rod, starting at 4 rpm and accelerated linearly to 40 rpm over 300 seconds. 
 
-  Activity cage test: 
The basal activity counts of rats were pretested in a 15 minutes interval the day before the experiment to habituate 
them to the apparatus; they were adapted for 5 minutes and the basal activity counts were then recorded for 10 
minutes [37]. Twenty four hours after the last injection of the tested drugs, each rat was then exposed to the 
apparatus for 10 minutes test session. The arena was cleaned after each session [31]. Locomotor activity was 
calculated as the total rat activity counts during 10 minutes using grid floor detecting activity cage. 
 
Brain tissue preparation: at the end of the experiment, twenty four hours after last injection of treatments rats were 
decapitated, their brains were carefully removed and both hemispheres were isolated according to the method 
described by [51]. Isolated striata were weighed and immediately frozen on dry ice then stored at -80˚C. for determination of 
biochemical analysis and oxidative stress biomarkers  
 
Biochemical analysis of the brain tissue homogenate: left striata homogenate was used for the determination of brain 
neurotransmitters [dopamine (DA), 3,4 dihydroxyphenylacetic acid (DOPAC), homovanilic acid (HVA) contents] (Perkin- 
Elmer, USA). While, right striata homogenate was used for assessment of oxidative stress biomarkers [reduced glutathione, 
malondialdehyde and nitric oxide content] as fellow:- 
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Estimation of brain neurotransmitters 
Dopamine and its metabolite contents: dopamine and its metabolites (DOPAC and HVA) in striatal homogenate 
were determined according to the method described by Pagel et al., [57]. Dopamine turnover was calculated 
according to the method described by Zbarsky et al., [ 84].  
 
Estimation of oxidative stress biomarkers:-  
 1.Glutathione content 
GSH in striatal homogenate was determined according to the method described by Ahmed et al., [3 ]. 
 
2. Malondialdehyde content 
Determination of lipid peroxides formation was measured in brain homogenate as thiobarbituric acid reactive 
substances (TBARS) according the method of Mihara and Uchiyama [49]. 
 
3. Nitric oxide (NOx) content 
Nitric oxide was determined according to the method described by Miranda et al., [50]. 
 
Statistical Analysis 
All the values are presented as means ± standard error of the means (mean ± s.e). Comparison between more than 
two different groups was carried out using the parameteric one-way analysis of variance (ANOVA) followed by 
Tukey HSD multiple comparisons test. For behavioral parameters, square root transformed percent was calculated 
[34] then comparison between more than two different groups was carried out using the non-parameteric one-way 
analysis of variance (ANOVA) followed by Dunn's multiple comparisons test. Difference was considered significant 
when P is less than 0.05. SPSS software (version 7.5) and INSTAT software (version 2) were used to carry out these 
statistical tests. 
 
RESULTS 
 
1. Effect of naringenin, harmine and adenosine treatment in locomotor activity and motor coordination in 
rotenone-treated rats 
Locomotor activity  
Subcutaneous injection of rotenone (1.5 mg/kg, s.c) for eleven days on every other day for a total of six injections 
significantly decreased the locomotor activity of rats reaching 34.57 % of their basal locomotor activity. Both 
deprenyl and naringenin significantly improved rats' locomotor activity to be 150 % and 130.6 % of that in the 
control (rotenone) group. While, both harmine and adenosine significantly decreased the locomotor activity of rats 
to be 72.5 % and 58.1 % of that in the rotenone control group (Table 1). 
 
Motor coordination  
Rotenone injection significantly decreased the balancing time of rats reaching 35.80 % of their basal balancing time. 
Simultaneous injection of deprenyl or harmine with rotenone increased rats' balancing time to103.49 and 111.76 % 
of their basal balancing time respectively. On the other hand, naringenin (50 mg/kg, p.o) or adenosine injection 
together with rotenone decreased the basal balancing time of rats to be 64.31 and 56.7 % of their basal balancing 
time respectively. Both deprenyl and harmine significantly improved rats balancing time to be 171.18 and 177.96 % 
of that in the control group. While, both naringenin and adenosine didn't have a significant effect on the balancing 
time of rats as compared to control group (Table 2). 
  
2. Effect of naringenin, harmine and adenosine on dopamine (DA), 3, 4 dihydroxyphenylacetic acid (DOPAC), 
homovanilic acid (HVA) contents in the striata of rotenone-treated rats 
Rotenone injection decreased dopamine content in the rats striata to 1.67±0.09 µg/g wet weight as compared to normal group, 
in which dopamine content was 7.29± 0.28 µg/g wet weights. Similarly, DOPAC and HVA contents were reduced to 
0.11±0.007 and 0.024±0.002 µg/g wet weight respectively in the rotenone-treated rats, compared to that in the normal group 
which was 0.76±0.03 and 0.046±0.03 µg/g wet weight respectively. On the other hand, dopamine turnover rate (TO), showed 
any significant changed in rotenone-treated rats when compared to the normal group . 
 
Oral administration of naringenin , together with rotenone  injection significantly increased dopamine content in rat striata to 
518.56 % of the control group, while DOPAC and HVA contents didn't significantly change as compared to control group. 
On the other hand, dopamine turnover rate was significantly decreased to 13.75 % control group (Table 3). Also 
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administration of harmine simultaneously with rotenone injection  was associated with a significant increase in dopamine 
content to 690.04 % and a significant decrease of dopamine turnover to 11.25 % of the control group. While dopamine 
metabolites didn't significantly change as compared to control group (Table 4). On the other hand, adenosine  injected 
simultaneously with rotenone didn't induce any significant change in the level of dopamine, DOPAC,  HVA nor the rate of 
dopamine turnover as compared to control group (Table 5) . 
 
3. Effect of naringenin, harmine and adenosine treatment on oxidative stress biomarkers in rotenone-treated 
rats  
1. The effect on reduced glutathione content  
Rotenone injection significantly decreased glutathione content to 0.026±0.001 mg/g wet weight compared to normal 
group in which glutathione content was 0.075±0.002 mg/g wet weight. Deprenyl injected   simultaneously with 
rotenone, induced a significant increase in glutathione content to 223.07 % of the control group. Similarly, 
simultaneous administration of naringenin with rotenone injection showed a significant increase in glutathione 
content to 284.61% of the control group (Table6). Administration either of harmine (Table 7) and adenosine (Table 
8) simultaneously with rotenone significantly increased glutathione content to 211.53 and 326.92 % respectively of 
control group. 
 
2. The effect on malondialdehyde (MDA) content:  
Injection of rotenone (1.5 mg/kg, s.c) for eleven days on every other day for a total of six injections significantly 
increased malondialdehyde content to146.35±11.38 nmol/ml wet weight compared to normal group in which 
malondialdehyde content was 40.75±4.33 nmol/ml wet weight. The injection of deprenyl (10 mg/kg, s.c) 
simultaneously with rotenone induced a significant decrease in malondialdehyde content in the rat striata to 31.02 % 
of control group. Similarly, simultaneous administration of naringenin (50 mg/kg, p.o), harmine (5mg/kg, i.p) and 
adenosine (500mg/kg, i.p) with rotenone showed a significant decrease in malondialdehyde content to 54.92, 29.44 
and 82.36 % respectively compared to that in the control group ( Table 6,7,8).  
 
3. The effect on nitric oxide (NOx) content: 
Rotenone subcutaneously injected at a dose of (1.5 mg/kg) for eleven days on every other day for a total of six 
injections didn't significantly decrease nitric oxide content compared to normal group. Deprenyl (10 mg/kg, s.c) 
simultaneously injected with rotenone didn't affect   nitric oxide content in the rat striata as compared to control 
group. In addition, combination of rotenone with any of the three agents didn't induce any significant change in 
nitric oxide level as compared to control group. On the other hand, deprenyl, naringenin, harmine and adenosine as 
compared to normal group (Table 6, 7, 8). 
 
DISCUSSION 
 
In the present study, injection of rotenone (1.5 mg/kg, s.c) into rats for eleven days on every other day for a total of 
six injections resulted in a significant decrease in locomotor activity tested by the activity cage. These findings are in 
agreement with Fleming et al. [20]. Also, rotenone treated rats, induced a decrease in the time spent on the rotarod 
and  these results are in accordance with a previous study that showed that rotenone (1.5 mg/kg, s.c) injected every 
other day for eleven days showed a decrease in muscle coordination and stayed for a shorter period on rotarod as 
compared to the normal animals [16]. As regard striatal dopamine concentrations rotenone injection induced a 
decrease to 22.9 % and these findings are in   consistent with those obtained by Abd El-Gawad et al. [1]. Concerning 
dopamine metabolites (DOPAC and HVA), results of the present study showed a significant decrease in DOPAC 
and HVA levels in striatum after rotenone treatment while ,DA turnover ( the ratio DOPAC+ HVA/DA) wasn't 
significantly changed. These results  may be attributed to a defect in substantia nigra pars compacta (SNc)  that may 
result in a decreased capacity to release DA in the striatum and thus a decrease in its metabolites content [79].In the 
present study, striatal GSH content was reduced to 34.66 % in the rotenone treated group as compared to the normal 
group. This finding is in harmony with a previous study reporting that rotenone induced about 49 % decrease in the 
GSH levels in substantia nigra and 26% decrease in neucleus caudatus putamen on the fifth day of rotenone 
injection [62]. Rotenone treated rats in current study showed a marked increase in the tissue MDA content, the 
decomposition product of lipid peroxidation and these results in agreement with Bashkatova et al. [5].As regard NO 
content assessment in the striatal tissue showed no change and these findings are in harmony with Cutillas et al. [11] 
and Gao et al. [23]. Fleming and his co-workers,[20] suggested that it is possible that rotenone may affect dopamine 
transporter activity and influence the expression and activity of striatal enzymes involved in dopamine synthesis. 
Therefore, it is possible that the motor abnormalities observed following rotenone treatment in the current study 
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were caused by alterations in the nigrostriatal dopaminergic system; they also speculated that other systems may be 
affected. The understanding of the mechanisms underlying rotenone-induced dopaminergic neuronal death could 
provide some insights into the processes responsible for the selective neurodegeneration of nigrostriatal 
dopaminergic neurons in PD patients. It is widely believed that increased oxidative stress and mitochondrial 
dysfunction contribute to dopaminergic neuronal degeneration. Although dopaminergic neurons are more sensitive 
to rotenone toxicity than other neurons [2, 60].These observations are consistent with  other report demonstrating 
that energy deprivation rather than ROS may be a main mechanism of rotenone-induced cell death in dopaminergic 
neurons [41] The results of the present study revealed that deprenyl (10 mg/kg, s.c) injected in rotenone-treated rats 
reversed bradykinesia and prolonged the time spent on the rod. Similarly, Engberg et al. [18] who reported that 
administration of deprenyl (3-30 mg/kg, i.p.) to normal rats caused a dose-dependent increase in the spontaneous 
locomotor activity. The improvement in rats' behavior following deprenyl treatment could be explained through its 
capacity to protect dopaminergic neurons from the toxic effects of rotenone and the increase in dopamine content 
[29]. Deprenyl was initially used in the treatment of PD based on its ability to exert its neuroprotective effect 
through reducing the catabolism of dopamine by inhibition of MAO-B enzyme. Thereby, increasing dopamine level 
with a subsequent increased activity on D2 receptor [76] .In the current results , deprenyl induced a significant 
increase in dopamine content in striatum of rotenone treated rats accompanied with non significant change in 
dopamine metabolites (DOPAC and HVA). This finding is in accordance with Knoll [ 39 ].The increase in 
dopamine content obtained with deprenyl can be discussed on the basis of  inhibition of  the uptake of DA [ 85] 
which may be due to the high concentration of the R-(2)-amphetamine and desmesthylselegiline metabolites of 
deprenyl or the accumulation of an endogenous factor such as beta-phenylethylamine, both are potent uptake 
inhibitors and have been suggested to play a role in the protective effects of deprenyl against MPTP and 6-OHDA 
toxicity in vivo [4, ,27,71].  The results of the present study also revealed that administration of deprenyl (10 mg/kg, 
s.c) in rotenone-treated rats reversed the oxidative stress induced by rotenone observed through an increase of 
glutathione and reduced MDA content in rats striata. This result is in accordance with Olanow et al. [56]. The 
neuroprotective effect of deprenyl might be due to its ability to prevent free radical formation, enhance the activity 
of antioxidant enzymes such as SOD and CAT, protects against peroxynitrite and nitric oxide induced apoptosis by 
up-regulation of antiapoptotic and antioxidant molecules, in addition of being a free radical scavenger [  15 , 53, 66, 
77].In the current  work, naringenin (50 mg/kg, p.o) significantly increased locomotor activity of rats but didn't 
affect motor coordination of rotenone- treated rats as compared to control groups. In addition, it induced significant 
increase in dopamine content in striatum to 518.56 % while dopamine metabolites (DOPAC and HVA) didn’t 
significantly change as compared to control group. Naringenin significantly increased glutathione level, decreased 
MDA level, while no change in nitric oxide contents compared to control group.  It was reported that certain 
flavanones, hesperitin and naringenin were able to pass the BBB and exert a useful chemopreventive action against 
neurodegenerative disease [30 , 81].Beyond the very potent ROS direct scavenger action, flavonoids exert an 
important indirect antioxidant activity contributing to the homeostasis of calcium, metal chelation, stabilisation of 
membranes through anti-lipoperoxidation and enzymatic activity modulation [ 8,10, 24]. In addition, they have anti-
inflammatory properties which can modulate both neurodegenerative and vascular diseases [48, 59]. In the present 
study, injection of harmine (5mg/kg, i.p) in rats didn’t reverse hypomotility induced by rotenone while, motor 
coordination was significantly improved as compared to control group. In agreement with these results is [68].In the 
present study, injection  of harmine (5 mg/kg, s.c) induced an increase in dopamine to 158.16 % while there was no 
significant change in dopamine metabolites level, these results are  in accordance with those previously reported  by 
Iurlo et al  [32] While  it increased the  reduced glutathione to 211.53 % and decreased MDA content to 29.44 % as 
compared to control (rotenone) group, without effects on  nitric oxide level. These findings are in agreement with 
Young Su Han et al [82] who stated that harmine increased GSH content in vitro. Several studies revealed that beta-
carbolines have effective antioxidant abilities by its radical scavenging properties. They are found to inhibit lipid 
peroxidation of liver microsomes [73] and to attenuate oxidative damage of hyaluronic acid, cartilage collagen and 
immunoglobulin G [38]. In addition, it was shown that harmalol had a protective effect against MPTP-induced 
neurotoxicity in the mouse [42]. Adenosine tretment in current study didn’t improve the behavior of rotenone–
treated rats and these effects can be explained by that adenosine plays a role opposite to dopamine in the striatum. 
Both dopamine antagonists and adenosine agonists produce similar effects in different behavioural tests. This was 
first pointed out by Heffner et al. [28], who found that some adenosine analogues attenuated spontaneous locomotor 
activity and didn't impair motor coordination in mice. Current study revealed that injection of adenosine (500 mg/kg, 
i.p) in rats treated with rotenone showed no change in dopamine and its metabolites levels in striatum compared to 
rotenone control. While it induced increase in glutathione levels and decrease in MDA levels while didn’t alter nitric 
oxide content in rats treated with rotenone. These  results in harmony with Zafar et al.  [83] who  reported that treating 
rats with different doses of adenosine decreased the levels of lipid peroxides and elevated the level of reduced glutathione 
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in sustantia nigra of 6-OHDA lesioned rats.It has been reported that adenosine acts as an endogenous activator of the 
cellular antioxidant system [ 26, 44] and inhibits the superoxide anion radical generation by neutrophils [ 9,26] and 
has scavenger properties against hydroxyl free radical. 
 
Table (1): Effect of naringenin, harmine and adenosine on locomotor activity tested by using activity cage 
 
Parameters 
Treatment 
Locomotor activity 
Activity Count % of basal activity 
Before treatment After treatment Percentage Square-root- transformed % 
Normal group 
(vehicle) 175.12±20.97 174.62±5.85
 99.7% 0.98 ± 0.04 
Control (rotenone) 
(1.5 mg/kg, s.c) 180.37±24.82 62.37±2.21 34.57% 0.62 ± 0.04
*
 
Deprenyl 
(10mg/kg, s.c) 
+rotenone 
(1.5mg/kg, s.c) 
234.62±15.39 199.12±14.10 84.86% 0.93 ± 0.05@ 
Naringenin 
(50mg/kg, p.o) 
+rotenone 
(1.5mg/kg, s.c) 
229.13±12.45 147.00±11.28 64.19% 0.81 ± 0.05@ 
Harmine 
(5mg/kg, i.p) 
+rotenone 
(1.5 mg/kg, s.c) 
148.62±5.54 29.87±7.21 20.1% 0.45 ± 0.01@* 
Adenosine 
(500mg/kg, i.p) 
+rotenone 
(1.5 mg/kg, s.c) 
297.50±24.67 37.12±6.15 12.47% 0.36 ± 0.02@* 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05 
 
Rats were given rotenone (1.5 mg/kg, s.c) either alone or simultaneously with deprenyl (10 mg/kg, s.c), naringenin 
(50 mg/kg, p.o), harmine (5 mg/kg, i.p) or adenosine (500 mg/kg, i.p) for eleven days on every other day for a total 
of six injections. Data was expressed as mean of 15 animals ± SE. Statistical analysis was carried out by one way 
ANOVA followed by Dunn's multiple comparisons test.  
 
Table (2): Effect of naringenin, harmine and adenosine on motor coordination tested by using rotarod in rotenone-treated rats 
 
Parameters 
Treatment 
Balancing time on the Rotarod 
Balancing  time % of basal time 
Before treatment After treatment Percentage Square-root- transformed % 
Normal group 
(vehicle) 234.37±17.53 235.54±16.30
 100.5 % 1.01 ± 0.01 
Control (rotenone) 
(1.5 mg/kg,s.c) 217.50±11.40 77.87±13.32
 35.80 % 0.59 ± 0.03* 
Deprenyl 
(10mg/kg,s.c) 
+rotenone 
(1.5mg/kg,s.c) 
202.83±14.17 209.91±21.30 103.49 % 1.01 ± 0.05@ 
Naringenin 
(50mg/kg,p.o) 
+ rotenone 
(1.5mg/kg,s.c) 
167.45±15.16 107.70±5.97 64.31 % 0.82 ± 0.06 
Harmine 
(5mg/kg,i.p) 
+rotenone 
(1.5 mg/kg) 
152.66±5.77 170.62±17.80 111.76 % 1.05 ± 0.06@ 
Adenosine 
(500mg/kg,i.p) 
+rotenone 
(1.5 mg/kg,s.c) 
221.25±19.85 125.45±35.77 56.7 % 0.75 ± 0.09 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05. 
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Rats were given rotenone (1.5 mg/kg, s.c) either alone, with deprenyl (10 mg/kg, s.c), naringenin (50 mg/kg, p.o), 
harmine (5 mg/kg, i.p) or adenosine (500mg/kg,i.p) for eleven days on every other day for a total of six injections. 
Data was expressed as mean of 15 animals±SE. Statistical analysis was carried out by one way ANOVA followed 
by Dunn's multiple comparisons test. 
 
Table (3): Effect of naringenin on dopamine (DA), 3,4 dihydroxy-phenylacetic acid (DOPAC), homovanilic acid (HVA) contents and its turnover rate 
(TO) in the striata of rotenone-treated rats 
 
Parameters 
Treatment 
 
DA(ug/gm) 
 
DOPAC(ug/gm) 
 
HVA(ug/gm) 
 
TO 
Normal group 
(vehicle) 7.29±0.28
 0.76±0.03 0.046±0.03 0.11±0.008 
Control(rotenone) 
(1.5 mg/kg,s.c) 1.67±0.09
* 0.11±0.007* 0.024±0.002* 0.08±0.006 
Deprenyl 
(10 mg/kg,s.c) 
+rotenone 
(1.5 mg/kg,s.c) 
4.27±0.11@* 0.31±0.034* 0.027±0.002* 0.07±0.008 
Naringenin 
(50 mg/kg,p.o) 
+rotenone 
(1.5mg/kg,s.c) 
8.66±0.52@ 0.07±0.006* 0.027±0.002* 0.011±0.0003@* 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05. 
TO=turnover= rate of dopamine turnover calculated as (HVA+DOPAC)/DA 
 
Rats were given rotenone (1.5 mg/kg, s.c) either alone or simultaneously with deprenyl (10 mg/kg, s.c) or naringenin 
(50 mg/kg, p.o) for eleven days on every other day for a total of six injections. Data was expressed as mean of 6 
animals ± SE. Statistical analysis was carried out by one way ANOVA followed by Tukey HSD multiple 
comparisons test. 
 . 
Table (4): Effect of harmine on dopamine (DA), 3,4 dihydroxy-phenylacetic acid (DOPAC), homovanilic acid (HVA) contents and its turnover rate 
(TO) in the striata of rotenone-treated rats 
 
Parameters 
Treatment DA(ug/gm) DOPAC(ug/gm) HVA(ug/gm) TO 
Normal group 
(vehicle) 7.29±0.28
 0.76±0.03 0.046±0.03 0.11±0.008 
Control(rotenone) 
(1.5 mg/kg,s.c) 1.67±0.09
* 0.11±0.007* 0.024±0.002* 0.08±0.006 
Deprenyl 
(10 mg/kg,s.c) 
+rotenone 
(1.5 mg/kg,s.c) 
4.27±0.11@* 0.31±0.034* 0.027±0.002* 0.07±0.008 
Harmine 
(5mg/kg,i.p) 
+rotenone 
(1.5 mg/kg) 
11.53±1.00@* 0.10±0.01* 0.015±0.002* 0.009±0.001@* 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05. 
TO=turnover= rate of dopamine turnover calculated as (HVA+DOPAC)/DA. 
 
Rats were given rotenone (1.5 mg/kg, s.c) either alone or simultaneously with deprenyl (10 mg/kg, s.c) or harmine 
(5 mg/kg, i.p) for eleven days on every other day for a total of six injections. Data was expressed as mean of 6 
animals±SE. Statistical analysis was carried out by one way ANOVA followed by Tukey HSD multiple 
comparisons test. 
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Table (5): Effect of adenosine on dopamine (DA), 3,4 dihydroxyphenylacetic acid (DOPAC), homovanilic acid (HVA) contents and its 
turnover rate (TO) in the striata of rotenone-treated rats 
 
Parameters 
Treatment 
DA 
(ug/gm) 
DOPAC 
(ug/gm) 
HVA 
(ug/gm) TO 
Normal group 
(vehicle) 7.29±0.28
 0.76±0.03 0.046±0.03 0.11±0.008 
Control(rotenone) 
(1.5 mg/kg,s.c) 1.67±0.09
* 0.11±0.007* 0.024±0.002* 0.08±0.006 
Deprenyl 
(10 mg/kg,s.c) 
+rotenone 
(1.5 mg/kg,s.c) 
4.27±0.11@* 0.31±0.034* 0.027±0.002* 0.07±0.008 
Adenosine 
(500mg/kg,i.p) 
+rotenone 
(1.5 mg/kg,s.c) 
1.96±0.13* 0.13±0.005* 0.038±0.002 0.085±0.007 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05. 
TO=turnover= rate of dopamine turnover calculated as (HVA+DOPAC)/DA 
 
Rats were given rotenone (1.5 mg/kg, s.c) either alone or simultaneously with deprenyl (10 mg/kg, s.c) or with 
adenosine (500 mg/kg, i.p) for eleven days on every other day for a total of six injections. Data was expressed as 
mean of 6 animals ±SE. Statistical analysis was carried out by one way ANOVA followed by Tukey HSD multiple 
comparisons test. 
 
Table (6): Effect of naringenin on glutathione (GSH), malondialdehyde (MDA) and nitric oxide (NOx) content in striata of rotenone-
treated rats 
 
Parameters 
Treatment 
GSH 
(mg/ml) 
MDA 
(nmol/ml) 
NO 
(µmol/l) 
Normal group 
(vehicle) 0.075±0.002
 40.75±4.33 40.17±4.02 
Control(rotenone) 
(1.5 mg/kg,s.c) 0.026±0.001
* 146.35±11.38* 29.44±3.60 
Deprenyl 
(10 mg/kg,s.c) 
+rotenone 
(1.5 mg/kg,s.c) 
0.058±0.007@ 45.40±3.01@ 16.92±0.57* 
Naringenin 
(50mg/kg,p.o) 
+rotenone 
(1.5 mg/kg,s.c) 
0.074±0.01@ 80.38±2.85@* 19.57±2.54* 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05 
 
Rats were given rotenone (1.5 mg/kg, s.c ) either alone or simultaneously  with deprenyl (10 mg/kg, s.c) or  with 
naringenin (50 mg/kg, p.o) for eleven days on every other day for a total of six injections. Data was expressed as 
mean of 6-8 animals±SE. Statistical analysis was carried out by one way ANOVA followed by Tukey HSD multiple 
comparisons test. 
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Table (7): Effect of harmine on glutathione (GSH), malondialdehyde (MDA) and nitric oxide (NOx) content in striata of  rotenone-
treated rats 
 
Parameters 
Treatment 
GSH 
(mg/ml) 
MDA 
(nmol/ml) 
NO 
(µmol/l) 
Normal group 
(vehicle) 0.075±0.002
 40.75±4.33 40.17±4.02 
Control(rotenone) 
(1.5 mg/kg,s.c) 0.026±0.001
* 146.35±11.38* 29.44±3.60 
Deprenyl 
(10 mg/kg,s.c) 
+rotenone 
(1.5 mg/kg,s.c) 
0.058±0.007@ 45.40±3.01@ 16.92±0.57* 
Harmine 
(5mg/kg,i.p) 
+rotenone 
(1.5 mg/kg,s.c) 
0.055±0.004@ 43.10±1.15@ 19.14±0.96* 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05. 
 
Rats were given rotenone (1.5 mg/kg, s.c) either alone or simultaneously with deprenyl (10 mg/kg, s.c) or with 
harmine (5 mg/kg, i.p) for eleven days on every other day for a total of six injections. Data was expressed as mean 
of 6-8 animals±SE. Statistical analysis was carried out by one way ANOVA followed by Tukey HSD multiple 
comparisons test. 
 
Table (8): Effect of adenosine on glutathione (GSH), malondialdehyde (MDA) and nitric oxide (NOx) content in striata of rotenone-
treated rats 
 
Parameters 
Treatment 
 
GSH 
(mg/ml) 
 
MDA 
(nmol/ml) 
 
NO 
(µmol/l) 
Normal group 
(vehicle) 0.075±0.002
 40.75±4.33 40.17±4.02
 
 
Control(rotenone) 
(1.5 mg/kg,s.c) 0.026±0.001
* 146.35±11.38* 29.44±3.60 
Deprenyl 
(10 mg/kg,s.c) 
+rotenone 
(1.5 mg/kg,s.c) 
0.058±0.007@ 45.40±3.01@ 16.92±0.57* 
Adenosine 
(500mg/kg,i.p) 
+rotenone 
(1.5 mg/kg,s.c) 
0.085±0.01@ 120.54±5.85*@ 19.35±1.49* 
*Significantly different from the corresponding normal group values at p<0.05. 
@
 Significantly different from the corresponding control (rotenone) group values at p<0.05. 
 
Rats were given rotenone (1.5 mg/kg, s.c) either alone or simultaneously with deprenyl (10 mg/kg ,s.c ) or  with 
adenosine (500 mg/kg,i.p) for eleven days on every other day for a total of six injections. Data was expressed as 
mean of 6-8 animals ±SE. Statistical analysis was carried out by one way ANOVA followed by Tukey HSD 
multiple comparisons test. 
 
CONCLUSION 
 
In this study, the ability of naringenin and harmine to ameliorate rotenone-induced behavioral and biochemical 
disturbance add weight to the evidence supporting the pathologic role of dopamine and oxidative stress in the 
development of parkinsonism. 
 
So, the present findings suggested that all three tested agents improved the oxidative status induced by rotenone. 
However, naringenin and harmine counteracted the decrease in dopamine content an effect that was reflected on the 
rats' behavior. 
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